De-escalating natalizumab ( NTZ ) to interferon beta 1b ( IFN B 1B ) is a possible treatment option in multiple sclerosis ( MS ) patients interrupting NTZ because of increased risk of progressive multifocal leukoencephalopathy ( PML ) .